Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. 1997

M Robinson, and A L Hemming, and J A Regnis, and A G Wong, and D L Bailey, and G J Bautovich, and M King, and P T Bye
Respiratory Investigation Unit, Royal Prince Alfred Hospital, Sydney, Australia.

BACKGROUND Patients with cystic fibrosis are known to have decreased mucociliary clearance. It has previously been shown that inhalation of a 7.0% solution of hypertonic saline significantly improved mucociliary clearance in a group of adult patients with cystic fibrosis. The aim of this study was to measure the response to increasing concentrations of inhaled hypertonic saline. METHODS Ten patients (seven men) of mean (SE) age 22 (4) years and mean forced expiratory volume in one second (FEV1) 52.0 (6.7)% predicted completed the study. Mucociliary clearance was measured using a radioaerosol technique for 90 minutes after the interventions which comprised 0.9% NaCl + voluntary cough (control), 3.0% NaCl, 7.0% NaCl, and 12% NaCl. RESULTS There was a significant increase in the amount of activity cleared from the right lung with all concentrations of hypertonic saline (HS) compared with control. The amount cleared at 90 minutes on the control day was 12.7% (95% confidence interval (CI) 9.8 to 17.2) compared with 19.7% (95% CI 13.6 to 29.5) for 3% HS, 23.8% (95% CI 15.9 to 36.7) for 7% HS and 26.0% (95% CI 19.8 to 35.9) for 12% HS. The improvement in mucociliary clearance was not solely due to coughing as the number of coughs recorded on the control day exceeded that recorded on any other day. The hypertonic saline did not induce a clinically significant change in FEV1. CONCLUSIONS Within the range of concentrations examined in this study, the effect of hypertonic saline appears to be dose dependent. Inhalation of hypertonic saline remains a potentially useful treatment for patients with cystic fibrosis.

UI MeSH Term Description Entries
D008297 Male Males
D009079 Mucociliary Clearance A non-specific host defense mechanism that removes MUCUS and other material from the LUNGS by ciliary and secretory activity of the tracheobronchial submucosal glands. It is measured in vivo as mucus transfer, ciliary beat frequency, and clearance of radioactive tracers. Mucociliary Transport,Clearance, Mucociliary,Clearances, Mucociliary,Mucociliary Clearances,Mucociliary Transports,Transport, Mucociliary,Transports, Mucociliary
D003550 Cystic Fibrosis An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION. Mucoviscidosis,Cystic Fibrosis of Pancreas,Fibrocystic Disease of Pancreas,Pancreatic Cystic Fibrosis,Pulmonary Cystic Fibrosis,Cystic Fibrosis, Pancreatic,Cystic Fibrosis, Pulmonary,Fibrosis, Cystic,Pancreas Fibrocystic Disease,Pancreas Fibrocystic Diseases
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D005541 Forced Expiratory Volume Measure of the maximum amount of air that can be expelled in a given number of seconds during a FORCED VITAL CAPACITY determination . It is usually given as FEV followed by a subscript indicating the number of seconds over which the measurement is made, although it is sometimes given as a percentage of forced vital capacity. Forced Vital Capacity, Timed,Timed Vital Capacity,Vital Capacity, Timed,FEVt,Capacities, Timed Vital,Capacity, Timed Vital,Expiratory Volume, Forced,Expiratory Volumes, Forced,Forced Expiratory Volumes,Timed Vital Capacities,Vital Capacities, Timed,Volume, Forced Expiratory,Volumes, Forced Expiratory
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000280 Administration, Inhalation The administration of drugs by the respiratory route. It includes insufflation into the respiratory tract. Drug Administration, Inhalation,Drug Administration, Respiratory,Drug Aerosol Therapy,Inhalation Drug Administration,Inhalation of Drugs,Respiratory Drug Administration,Aerosol Drug Therapy,Aerosol Therapy, Drug,Drug Therapy, Aerosol,Inhalation Administration,Administration, Inhalation Drug,Administration, Respiratory Drug,Therapy, Aerosol Drug,Therapy, Drug Aerosol
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012462 Saline Solution, Hypertonic Hypertonic sodium chloride solution. A solution having an osmotic pressure greater than that of physiologic salt solution (0.9 g NaCl in 100 ml purified water). Hypertonic Saline Solution,Hypertonic Solution, Saline,Sodium Chloride Solution, Hypertonic,Hypertonic Saline Solutions,Hypertonic Solutions, Saline,Saline Solutions, Hypertonic,Sodium Chloride Solutions, Hypertonic,Saline Hypertonic Solution,Saline Hypertonic Solutions,Solution, Hypertonic Saline,Solution, Saline Hypertonic,Solutions, Hypertonic Saline,Solutions, Saline Hypertonic

Related Publications

M Robinson, and A L Hemming, and J A Regnis, and A G Wong, and D L Bailey, and G J Bautovich, and M King, and P T Bye
May 1996, American journal of respiratory and critical care medicine,
M Robinson, and A L Hemming, and J A Regnis, and A G Wong, and D L Bailey, and G J Bautovich, and M King, and P T Bye
September 2018, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society,
M Robinson, and A L Hemming, and J A Regnis, and A G Wong, and D L Bailey, and G J Bautovich, and M King, and P T Bye
September 2011, BMC pulmonary medicine,
M Robinson, and A L Hemming, and J A Regnis, and A G Wong, and D L Bailey, and G J Bautovich, and M King, and P T Bye
November 2020, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society,
M Robinson, and A L Hemming, and J A Regnis, and A G Wong, and D L Bailey, and G J Bautovich, and M King, and P T Bye
April 1997, The Laryngoscope,
M Robinson, and A L Hemming, and J A Regnis, and A G Wong, and D L Bailey, and G J Bautovich, and M King, and P T Bye
January 2000, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine,
M Robinson, and A L Hemming, and J A Regnis, and A G Wong, and D L Bailey, and G J Bautovich, and M King, and P T Bye
January 2006, The New England journal of medicine,
M Robinson, and A L Hemming, and J A Regnis, and A G Wong, and D L Bailey, and G J Bautovich, and M King, and P T Bye
January 2014, PloS one,
M Robinson, and A L Hemming, and J A Regnis, and A G Wong, and D L Bailey, and G J Bautovich, and M King, and P T Bye
July 2020, ERJ open research,
M Robinson, and A L Hemming, and J A Regnis, and A G Wong, and D L Bailey, and G J Bautovich, and M King, and P T Bye
January 1976, Modern problems in paediatrics,
Copied contents to your clipboard!